Pipeline - Theragnostics

Product Details

Theragnostics’ clinical lead, THG-001 (68Ga-THP-PSMA), is being developed with our proprietary Galli^® single-vial kit manufacturing technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine.

The Phase II trial of THG-001 is now complete. More information about this trial can be found on clinicaltrials.gov here.

A Phase III trial is currently being registered following Theragnostics meeting with the FDA in February 2019.

THG-002

(USA only) Kit for the production of 99mTc-DMSA. Due to the current critical shortage of DMSA Kit for the Preparation of Technetium Tc99m Succimer, Theragnostics Inc. (Theragnostics) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug. Theragnostics has initiated temporary importation of DMSA Kit for the Preparation of Technetium Tc99m Succimer Injection into the U.S. market. See our Products page for further information.

THG-008

THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (rPARPi) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. The first clinical study for THG-008 is in head and neck cancers completed recruitment in May 2019 and a manuscript is currently in preparation for publication in a peer-reviewed journal.
Further clinical studies are currently in plan for other oncology indications to take THG-008 into Phase II.

THG-009

Further updates will be added in due course.

THG-001

Theragnostics’ proprietary clinical lead, THG-001 (THP-PSMA), is being developed with our Galli^® technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine. THG-001 is now recruiting for a Phase II clinical trial.

More information about the trial can be found on clinicaltrials.gov here.

An article on diagnosing prostate cancer and recent advances in radiopharmaceutical imaging by Theragnostics CEO, Dr Greg Mullen was featured in Diagnostic Imaging Europe in November 2017.

THG-002

THG-008

THG-009